Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease

Thorax

Volumn 60, Issue 3, 2005, Pages 193-198

  Brightling, C E ^a   McKenna, S ^a   Hargadon, B ^a   Birring, S ^a   Green, R ^a   Siva, R ^a   Berry, M ^a   Parker, D ^a   Monteiro, W ^a   Pavord, I D ^a   Bradding, P ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; MOMETASONE FUROATE; PLACEBO; ANTIINFLAMMATORY AGENT; INTERLEUKIN 8; PREGNANE DERIVATIVE;

ADULT; AGED; ARTICLE; CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY DISEASE QUESTIONNAIRE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG RESPONSE; EOSINOPHILIA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; SPUTUM ANALYSIS; TREATMENT OUTCOME; BLOOD; CHEMISTRY; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; INHALATIONAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; PATHOLOGY; PHYSIOLOGY; SPUTUM;

ADMINISTRATION, INHALATION; AGED; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTERLEUKIN-8; LEUKOCYTE COUNT; MALE; PREGNADIENEDIOLS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

EID: 20144382091     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2004.032516     Document Type: Article

References (30)

1. Calverley PMA, Walker P. Chronic obstructive pulmonary disease. Lancet 2003;362:1053-61.
2. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001;163:1256-76.
3. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl I).
4. Pavord ID, Brightling CE, Woltmann G, et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999;353:2213-4.
5. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
6. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997;155:449-53.
7. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998;158:1511-7.
8. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-5.
9. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8.
10. Brightling CE, Ward R, Goh KL, et al. Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med 1999;160:406-10.
11. Brightling CE, Ward R, Woltmann G, et al. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med 2000;162:878-82.
12. Tweeddale PM, Alexander F, McHardy GJ. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987;42:487-90.
13. Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998;53:583-5.
14. Gizycki MJ, Hattotuwa KL, Barnes N, et al. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002;57:799-803.
15. Culpitt SV, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-9.
16. Loppow D, Schleiss MB, Kanniess F, et al. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001;95:115-21.
17. Yildiz F, Kaur AC, Ilgazali A, et al. Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration 2000;67:71-6.
18. Louis RE, Cataldo D, Buckley MG, et al. Evidence of most-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease. Eur Respir J 2002;20:325-31.
19. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-53.
20. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999;353:1819-23.
21. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
22. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease: Lung Health Study II. N Engl J Med 2000;343:1902-9.
23. Fan VS, Bryson CL, Curtis JR, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalisation: time-dependent analysis. Am J Respir Crit Care Med 2003;168:1488-94.
24. Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use fluticaone propionate and solmeterol in general practice. Eur Respir J 2002;20:819-25.
25. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
26. Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73.
27. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91.
28. Burge PS, Calverley PMA, Jones PW, et al. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003;58:654-8.
29. Pavord ID, Siva R, Brightling CE, et al. Prednisolone response in patients with COPD. Thorax 2004;59:179.
30. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.